A Phase 1 interventional study of CORT118335 Oral and 14C-CORT118335 intravenous in Healthy, sponsored by Corcept Therapeutics. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-11.
Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the absolute bioavailability of CORT118335 and determine the mass balance recovery, absorption, metabolism and elimination, and metabolite profile and identification of metabolite structures following a single oral dose of CORT118335 in healthy male participants.
Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, participants will receive a single oral dose of CORT118335 900 mg (Treatment A) after an overnight fast, and a 15-minute intravenous infusion of a microdose of 14C-CORT118335 (Treatment B) beginning 2 hours 45 minutes after the oral dose is administered.
Drug: CORT118335 Oral · Drug: 14C-CORT118335 intravenous
On Day 1, participants will receive a single oral dose of 14C-CORT118335 150 mg (Treatment C) after an overnight fast.
Drug: 14C-CORT118335 oral
CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
Also known as: Treatment A
14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C
Also known as: Treatment B
14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C
Also known as: Treatment C
Absolute Oral Bioavailability (F) of CORT118335
Time frame: Predose and at pre-specified time points up to Day 12
Mass Balance Recovery in Excreta After a Single Oral Dose of 14C-CORT118335
Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)
Mass Balance Recovery in Urine After a Single Oral Dose of 14C-CORT118335
Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)
Mass Balance Recovery in Feces After a Single Oral Dose of 14C-CORT118335
Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)
Pharmacokinetics (PK) of Total Radioactivity after Oral Dosing: Peak Plasma Concentration (Cmax)
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
PK of Total Radioactivity in Plasma after Oral Dosing: Time from Dosing to Cmax (tmax)
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
PK of Total Radioactivity after Oral Dosing: Area Under the Plasma Concentration-time Curve from Zero Time to Time of the Last Measurable Concentration (AUC0-last)
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
PK of Total Radioactivity in Plasma after Oral Dosing: Apparent Elimination Half-life (t1/2)
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
PK of Total Radioactivity in Plasma after Oral Dosing: Mean Residence Time (MRT)
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
PK of Plasma CORT118335 after Oral Dosing: Cmax
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
PK of Plasma CORT118335 after Oral Dosing: Tmax
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
PK of Plasma CORT118335 after Oral Dosing: AUC0-last
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
PK of Plasma CORT118335 after Oral Dosing: MRT
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
PK of Plasma 14C-CORT118335 after IV Dosing: Cmax
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
PK of Plasma 14C-CORT118335 after IV Dosing: AUC0-last
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
PK of Plasma 14C-CORT118335 after IV Dosing: t1/2
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
PK of Plasma 14C-CORT118335 after IV Dosing: Total Clearance (CL)
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
PK of Plasma 14C-CORT118335 after IV Dosing: MRT
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
PK of Total Radioactivity in Plasma after IV Dosing: Cmax
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
PK of Total Radioactivity in Plasma after IV Dosing: AUC0-last
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
PK of Total Radioactivity in Plasma after IV Dosing: t1/2
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
PK of Total Radioactivity in Plasma after IV Dosing: CL
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
PK of Total Radioactivity in Plasma after IV Dosing: MRT
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
PK in Plasma after IV Dosing: AUC0-last for 14C-CORT118335 / AUC0-last for Total Radioactivity
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Distribution of Total Radioactivity into Red Blood Cells after Oral Dosing
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
Number of CORT118335 Metabolites Accounting for >10% of Total Radioactivity Detected in Plasma, Urine, and Feces
Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)
Percentage of Participants with One or More Adverse Events
Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2018 to primary completion in Mar 2019, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CORT118335